A Phase 3 interventional study of N-acetyl cysteine and Metfomin in Polycystic Ovary Syndrome, sponsored by Cairo University. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Cairo University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Polycystic Ovary Syndrome by Cairo University — 10 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Cairo University.
Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 3, and was the 26th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →10 of the 34 studies in Polycystic Ovary Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–40 · Women only
Cairo University · Sites in Egypt
Ages 20–30 · Women only
Cairo University · Sites in Egypt
Ages 30–40 · Women only
Cairo University · Sites in Egypt
Ages 35–45 · Women only
Cairo University · Sites in Egypt
Ages 18–35 · Women only
By country, each count listing its studies:
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 55 across the 26 interventional studies, 98 across the 8 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Polycystic Ovary Syndrome by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07591246Cairo UniversityEfficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction | 2026-12-30 |
| NCT07708766Cairo UniversityEffect of High Intensity Interval Training on Insulin Resistance in Polycystic Ovarian Syndrome | 2027-01-15 |
| NCT07937202Cairo UniversityEffects of Pilates Exercises on Doppler Parameters in Obese Females With Polycystic Ovarian Syndrome | 2027-04-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate the effects of combination of metformin with NAC in PCOS on biochemical and hormonal parameters.
Polycystic ovarian syndrome (PCOS) is one of the prevalent endocrine illnesses that affects women in industrialized and developing nations, with a prevalence that ranges from 8% to 13%. The most widely accepted criteria for diagnosing polycystic ovary syndrome (PCOS) are the Rotterdam criteria established in 20032. According to these criteria, a diagnosis is made if a patient meets at least two of the following three criteria:
The Rotterdam criteria
Polycystic ovarian syndrome is diagnosed when 2 out of 3 criteria are met:
And exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome).
The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS has built on the Rotterdam criteria by emphasizing more comprehensive assessments.
These updates highlight the need to consider a broader range of phenotypes, assess metabolic risks, and prioritize patient-centered, individualized care.
Algorithm: Screening and diagnostic assessment
Step 1:
Irregular Menstrual Cycles + Clinical Hyperandrogenism
Step 2:
Irregular Menstrual Cycles Without Clinical Hyperandrogenism • Test for biochemical hyperandrogenism and exclude other causes* = Diagnosis
Step 3:
If Only Irregular Cycles or Only Hyperandrogenism
Adults: Ultrasound for Polycystic Ovarian morphology (PCOM)* OR Anti-Mullerian Hormone (AMH) level, if positive (exclude other causes) * = diagnosis
> 3 years post-menarche until perimenopause: Cycle length is either less than 21 days, more than 35 days, or fewer than 8 cycles per year.
> 1-year post-menarche: Any cycle lasting more than 90 days. Primary amenorrhea: no menstruation by age 15 or more than 3 years after the onset of breast development (thelarche).
Biochemical hyperandrogenism Elevated total or free testosterone, or calculated indices of free testosterone Clinical hyperandrogenism Comprehensive history and physical examination are needed. Adults: acne, female pattern hair loss, and hirsutism. Adolescents: severe acne and hirsutism.
Note the negative psychosocial impact of clinical hyperandrogenism. Standardized visual scales are preferred, including the modified Ferriman Gallway score (mFG), a score of ≥ 4-6 = hirsutism.
Ultrasound and polycystic ovary morphology (PCOM) and anti-mullerian hormone (AMH) Using ultrasound transducers with a frequency bandwidth including 8 MHz, the PCOM threshold is a follicle number per ovary of ≥ 20 and/or an ovarian volume ≥ 10 ml on either ovary, avoiding corpora lutea, cysts or dominant follicles.
Either serum AMH OR ultrasound may be used but not both to avoid overdiagnosis Serum AMH could be used for defining PCOM in adults as an alternative to pelvic or abdominal ultrasound.
People with PCOS often experience various metabolic and reproductive outcomes such as obesity, insulin resistance (IR), oxidative stress (OS), hirsutism, acne, irregular menstruation, and infertility, as well as long-term consequences including cancer and cardiovascular illnesses.
The cause of PCOS is still unknown, despite evidence indicating the pathophysiology of the condition is primarily driven by the production of high quantities of androgen and IR. Additionally, research showed that OS is linked to IR, hyperinsulinemia, hyperandrogenism, persistent inflammatory conditions, abnormalities in fat and carbohydrate metabolism, ovarian dysfunction, and unfavorable pregnancy outcomes. Consequently, antioxidant therapy might be useful in the management of PCOS. Patients with PCOS frequently seek treatment for a variety of symptoms, including menstrual irregularities, heavy menstrual bleeding, acne, hirsutism, and weight management challenges.
The management of PCOS is typically tailored to address these specific symptoms, with a range of therapeutic options available depending on the patient's presentation. Menstrual irregularity and heavy bleeding in patients with PCOS can be managed through lifestyle interventions, such as diet and exercise aimed at achieving a weight reduction of 5%-10%8, or by using combined hormonal contraceptives. These may include oral norethindrone acetate (5 mg daily for 7 days every 30-90 days, or 5 mg daily for 3 weeks on and 1 week off), ethinyl estradiol (20-35 mcg of ethinyl estradiol in combination with a progestin), or oral drospirenone (4 mg for 24 days, followed by 4 days of placebo). In cases where hormonal contraceptives are not suitable or effective, metformin (1500-2000 mg daily in divided doses, starting at 500 mg and increasing by 500 mg every 1-2 weeks) may be considered. Inositol supplementation, commonly administered as 4 g of myo-inositol daily, is another option that has been shown to improve menstrual regularity, metabolic disturbances, and reducing weight in patients with PCOS.
For managing acne, hirsutism, or alopecia, first-line treatments include combined hormonal contraceptives to address androgenic symptoms. In addition, topical treatments for hirsutism, such as 13% eflornithine, can help reduce unwanted facial hair. Minoxidil (2% solution, applied twice daily) is commonly used for the treatment of alopecia. Topical or oral acne treatments should follow general dermatological guidelines, depending on the severity of the condition.
Overweight or obesity is commonly addressed through lifestyle interventions. Metformin (1500-2000 mg daily in divided doses, with gradual titration starting at 500 mg) can be used to improve insulin sensitivity and aid in weight management.
For ovulation induction, letrozole (2.5 mg-7.5 mg for 5 days) is considered a first-line treatment for ovulation induction in many guidelines. To confirm successful ovulation, it is recommended to measure serum progesterone levels approximately 3 weeks after initiating letrozole. Metformin (1500-2000 mg daily) can also be used to enhance ovulatory function. Clomiphene is also used to induce ovulation, starting at 50 mg daily for 5 days from days 2-5 of the cycle. If ineffective, the dose may be increased to 100 mg or 150 mg in subsequent cycles for up to 6 cycles.
N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants. By promoting the synthesis of glutathione synthetase hormone (GSH), NAC helps inhibit OS, preventing hyperinsulinemia-induced IR and protecting insulin receptors from oxidative damage. NAC likely enhances insulin receptor activity, leading to increased glucose consumption, which indicates improved insulin sensitivity. IR, dyslipidemia, and hyperhomocysteinemia are risk factors for ischemic heart disease in women with PCOS. NAC has been utilized as a therapeutic agent to improve homocysteine levels and lipid profiles, which in turn have been shown to affect insulin receptor activity. As a result, the primary cause of PCOS was alleviated and insulin levels fell. The antioxidant properties of NAC have been utilized in multiple clinical trials conducted on infertile PCOS females to increase oocyte quality and ovulation rate.
In this study, the investigators will evaluate and compare the efficacy of metformin and NAC combination versus metformin alone on clinical, metabolic, hormonal, and biochemical aspects in patients with PCOS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group-MN, constituting 51 cases, will receive N-acetyl cysteine and metformin (600 mg three times daily of acetyl cysteine and 500 mg once daily for one week, then 500 mg twice daily for one week, and 500 mg three times daily thereafter of metformin)
Drug: N-acetyl cysteine · Drug: Metfomin
Group-M, constituting 51 cases, will receive treatment with metformin (starting with 500 mg once daily for one week, then 500 mg twice daily for one week, and 500 mg three times daily thereafter)
Drug: Metfomin
N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.
Also known as: NAC
metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.
Primary outcome will be change in LH/FSH levels.
change in LH/FSH ratio
Time frame: 3 months
improvement in hormonal levels in patients with PCOS
Hormonal profile change in: Total testosterone levels (ng/dL) Free testosterone levels (ng/dL) Free testosterone to total testosterone (FT/TT) ratio, calculated from the measured values.
Time frame: 3 months
improvement in clinical features in patients with PCOS
improvement in clinical features: Menstrual irregularities: improvement in oligomenorrhea or amenorrhea, assessed based on The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS Hirsutism: Assessed using the modified Ferriman-Gallwey (mFG) score Acne: Evaluated using the Investigator Global Assessment (IGA) scale technique.
Time frame: 3 months
improvement in biochemical parameters in patients with PCOS
biochemical parameters change in: Fasting insulin levels (µIU/mL). Fasting blood glucose (FBG) levels (mg/dL). Glucose/insulin ratio, calculated using fasting glucose and insulin levels. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated using the standard formula.
Time frame: 3 months
improvement in metabolic parameters in patients with PCOS
weight in kilograms, height in meters Body mass index (BMI) (kg/m2), calculated as weight (kg) divided by height (m2).
Time frame: 3 months
Plan to share: No
Ran from Mar 2025 to primary completion in Mar 2026, 12 months.
Of 26 non-industry phase 3 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 12 months is below that.
Counting every sponsor, half of 26 studies reached it within 28 months; a quarter within 11 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Feb 2026 → Mar 2026 and completion May 2026 → Mar 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine